We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients (NEO-ZOTAC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01099436
First Posted: April 7, 2010
Last Update Posted: July 16, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Dutch Cancer Society
Amgen
Sanofi
Novartis
Information provided by (Responsible Party):
Borstkanker Onderzoek Groep